“…Level I evidence for acute treatment of C1‐INH‐HAE has been reviewed for pdC1‐INH Be , pdC1‐INH Ci , recombinant human C1‐INH (rhC1‐INH) (Rhucin/Ruconest ® ), kallikrein inhibitor ecallantide (Kalbitor ® ), and bradykinin B2 receptor antagonist icatibant (Firazyr ® ) 85, 91, 92, 95, 96, 97, 98, 99. Unfortunately, these treatments have been licensed mainly for adults with pediatric licensing pending and ages for licenses varying by jurisdiction.…”